Cargando…

Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats

The neuroprotective effects of environmental enrichment and PACAP (pituitary adenylate cyclase-activating polypeptide) are well-described in Parkinson’s disease. The aim of our study is to investigate the beneficial effects of these factors in aging parkinsonian rats. Newborn Wistar rats were divide...

Descripción completa

Detalles Bibliográficos
Autores principales: Jungling, Adel, Reglodi, Dora, Maasz, Gabor, Zrinyi, Zita, Schmidt, Janos, Rivnyak, Adam, Horvath, Gabor, Pirger, Zsolt, Tamas, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827131/
https://www.ncbi.nlm.nih.gov/pubmed/33429934
http://dx.doi.org/10.3390/life11010035
_version_ 1783640688125018112
author Jungling, Adel
Reglodi, Dora
Maasz, Gabor
Zrinyi, Zita
Schmidt, Janos
Rivnyak, Adam
Horvath, Gabor
Pirger, Zsolt
Tamas, Andrea
author_facet Jungling, Adel
Reglodi, Dora
Maasz, Gabor
Zrinyi, Zita
Schmidt, Janos
Rivnyak, Adam
Horvath, Gabor
Pirger, Zsolt
Tamas, Andrea
author_sort Jungling, Adel
collection PubMed
description The neuroprotective effects of environmental enrichment and PACAP (pituitary adenylate cyclase-activating polypeptide) are well-described in Parkinson’s disease. The aim of our study is to investigate the beneficial effects of these factors in aging parkinsonian rats. Newborn Wistar rats were divided into standard and enriched groups according to their environmental conditions. Standard animals were raised under regular conditions. During the first five postnatal weeks, enriched pups were placed in larger cages with different objects. Aging animals received (1) saline, (2) 6-hydroxidopamine (6-OHDA), or (3) 6-OHDA + PACAP injections into the left substantia nigra (s.n.). On the seventh postoperative day, the left and right s.n. were collected. The s.n. of young and aging unoperated animals were also examined in our experiment. We determined the dopamine (DA) levels by the HPLC-MS technique, while the sandwich ELISA method was used to measure the Parkinson disease protein 7 (PARK7) protein levels. In healthy animals, we found an age-related decrease of DA levels. In aging parkinsonian-enriched rats, the operation did not result in a significant DA loss. PACAP treatment could prevent the DA loss in both the standard and enriched groups. All injured PACAP-treated rats showed remarkably higher protective PARK7 levels. The protective effect of PACAP correlated with the increase of the DA and PARK7 levels.
format Online
Article
Text
id pubmed-7827131
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78271312021-01-25 Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats Jungling, Adel Reglodi, Dora Maasz, Gabor Zrinyi, Zita Schmidt, Janos Rivnyak, Adam Horvath, Gabor Pirger, Zsolt Tamas, Andrea Life (Basel) Article The neuroprotective effects of environmental enrichment and PACAP (pituitary adenylate cyclase-activating polypeptide) are well-described in Parkinson’s disease. The aim of our study is to investigate the beneficial effects of these factors in aging parkinsonian rats. Newborn Wistar rats were divided into standard and enriched groups according to their environmental conditions. Standard animals were raised under regular conditions. During the first five postnatal weeks, enriched pups were placed in larger cages with different objects. Aging animals received (1) saline, (2) 6-hydroxidopamine (6-OHDA), or (3) 6-OHDA + PACAP injections into the left substantia nigra (s.n.). On the seventh postoperative day, the left and right s.n. were collected. The s.n. of young and aging unoperated animals were also examined in our experiment. We determined the dopamine (DA) levels by the HPLC-MS technique, while the sandwich ELISA method was used to measure the Parkinson disease protein 7 (PARK7) protein levels. In healthy animals, we found an age-related decrease of DA levels. In aging parkinsonian-enriched rats, the operation did not result in a significant DA loss. PACAP treatment could prevent the DA loss in both the standard and enriched groups. All injured PACAP-treated rats showed remarkably higher protective PARK7 levels. The protective effect of PACAP correlated with the increase of the DA and PARK7 levels. MDPI 2021-01-08 /pmc/articles/PMC7827131/ /pubmed/33429934 http://dx.doi.org/10.3390/life11010035 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jungling, Adel
Reglodi, Dora
Maasz, Gabor
Zrinyi, Zita
Schmidt, Janos
Rivnyak, Adam
Horvath, Gabor
Pirger, Zsolt
Tamas, Andrea
Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats
title Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats
title_full Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats
title_fullStr Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats
title_full_unstemmed Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats
title_short Alterations of Nigral Dopamine Levels in Parkinson’s Disease after Environmental Enrichment and PACAP Treatment in Aging Rats
title_sort alterations of nigral dopamine levels in parkinson’s disease after environmental enrichment and pacap treatment in aging rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827131/
https://www.ncbi.nlm.nih.gov/pubmed/33429934
http://dx.doi.org/10.3390/life11010035
work_keys_str_mv AT junglingadel alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT reglodidora alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT maaszgabor alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT zrinyizita alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT schmidtjanos alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT rivnyakadam alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT horvathgabor alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT pirgerzsolt alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats
AT tamasandrea alterationsofnigraldopaminelevelsinparkinsonsdiseaseafterenvironmentalenrichmentandpacaptreatmentinagingrats